Multiple Myeloma

The analysis, which was presented during the 64th ASH Annual Meeting and Exposition, highlighted stringent complete response data for patients 65 years and older and those with high cytogenic risk.

An analysis presented during the 64th American Society of Hematology Annual Meeting and Exposition showed that patients with multiple myeloma were able to experience improved responses to the proteasome inhibitor ixazomib after switching from bortezomib.

Dr Haumschild leads a discussion regarding frontline MM treatment products as categorized by NCCN.

Raymond Thertulien, MD, PhD, highlights provider incentives for adherence to MM treatment pathways.

A recent study found that ixazomib was associated with better progression-free survival versus a placebo in multiple myeloma regardless of cytogenetic risk status.

Omar Nadeem, MD, shares perspective on the significance of collaborative care in the MM treatment landscape.

A panel of experts discuss the value of clinical pathways in MM disease management.

An interview with Joseph R. Mikhael, MD, MEd, on findings from a Quality Improvement initiative presented during the 64th American Society of Hematology Annual Meeting and Exposition in New Orleans, Louisiana. Mikhael is a professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute, an affiliate of City of Hope Cancer Center, in Phoenix, Arizona.

Daratumumab can be an effective frontline MM treatment option.

Raymond Thertulien, MD, PhD, discusses high-risk factors for patients with MM.

Black Americans with multiple myeloma face disparities in incidence of disease, survival outcomes, and use of evidence-based treatment, which may be exacerbated by socioeconomic factors.

Despite greater incidence of multiple myeloma (MM) reported among Hispanic Americans, these populations report less MM maintenance therapy, longer time from MM diagnosis to novel therapy initiation, and higher in-hospital mortality rates.

Brea C. Lipe, MD, highlights considerations for frail patients when treating for MM.

Medical experts explore the SWOG-S0777 trial and present an overview of daratumumab in combination with lenalidomide and dexamethasone (DRd) vs bortezomib, lenalidomide, and low-dose dexamethasone (VRd).

The top 5 most-read articles on AJMC.com for 2022 covered COVID-19, the first treatment for repigmentation in vitiligo, migraine care, and vitamin D supplementation for patients with multiple myeloma.

M. Hossein Kazemi, MD, medical oncologist and hematologist, Astera Cancer Care, discusses the benefits of de-escalating treatment for patients with multiple myeloma.

M. Hossein Kazemi, MD, medical oncologist and hematologist, Astera Cancer Care, discusses emerging tools to use to identify patients with multiple myeloma for de-escalating treatment.

The most-read multiple myeloma (MM) articles of the year included the topics of novel treatments, the role of gene expression influence on MM, and more.

Ryan Haumschild, PharmD, MS, MBA, leads a panel in a conversation reviewing the MAIA study.

Key opinion leaders open a discussion surrounding the current treatment landscape of multiple myeloma (MM).

M. Hossein Kazemi, MD, medical oncologist and hematologist, Astera Cancer Care, identifies key tools in de-escalating treatment for patients with multiple myeloma.

Coverage from the Institute for Value-Based Medicine® session with Astera Cancer Care in Edison, New Jersey, held November 3, 2022.

Thirteen years of population-based data highlight substantial rates of aggressive end-of-life care and disparities in care within a publicly funded health care system in Ontario, Canada.

Their findings, say the researchers, offer useful insights into the outcomes and risks of severe disease and mortality in patients who have multiple myeloma (MM) or amyloidosis (AL) with underlying monoclonal gammopathy who contract COVID-19.

New data show patients treated with chimeric antigen receptor (CAR) T-cell therapy as salvage therapy tended to have meaningful results despite treatment failure following B-cell maturation antigen (BCMA) CAR T.